Roche said it will run a new Phase 3 trial for the controversial Duchenne muscular dystrophy gene therapy Elevidys in another attempt to win approval

💰 MeiraGTx buys back eye gene therapy from J&J for just $25M: The gene therapy, known as bota-vec, failed a Phase 3 study for X-linked

If you asked me a year ago to break down the different areas of healthcare AI we’re covering, it might’ve looked like scribes, clinical decision

A new Apposite Capital fund has been set up with £100m to provide much-needed scale-up funding for UK biopharma and healthtech companies.

As the prices paid for priority review vouchers (PRVs) have crept up over the past year — the last two have sold for at least